Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Feb 28, 2022; 28(8): 825-839
Published online Feb 28, 2022. doi: 10.3748/wjg.v28.i8.825
Table 1 Primer sequences, annealing temperature and product size for MS-PCR and EpiTYPER DNA methylation analysis of target genes
Genes
Forward primer (5’ → 3’)
Annealing temperature (°C)
Product size (bp)
SUMF2MF:TTTGATTATGGTCGGTTTTGC59.4191
R:GACTACTTACAACTCCCCTAACGAC
UF:TTTTTTGATTATGGTTGGTTTTGTG60.6198
R:CCCAACTACTTACAACTCCCCTAACA
QF:TTTGTTATAGAGGGATGGGAGATAG aggaagagag60232
R:CAAAATAAACAACACTCCAAATTCA cagtaatacgactcactatagggagaaggct
ADAMTS5MF:GTTATTGTCGTGGAGCGTTAGC59.4170
R:CCTACCTCCCGTACTTCCCG
UF:TTATTGTTGTGGAGTGTTAGTGTTT59.4169
R:CCTACCTCCCATACTTCCCACAT
QF:aggaagagagTTGAAATTGTTATTGTAGGATGGTATG61.3245
R:cagtaatacgactcactatagggagaaggctAATTAAAACAAAAATACAAAAAAACAACC
PXDNMF:TATGCGGGACGAGAACGAGA61.6137
R:ACTTAAACAACTCCGTAACAATACGAT
UF:GTGTATGTGGGATGAGAATGAGAG60.4142
R:CAACTTAAACAACTCCATAACAATACAA
Table 2 Characteristics and distribution of methylation status in patients with colorectal cancer (n = 208)
Characteristics
Total
Methylation status
SUMF2
ADAMTS5
PXDN
Normal
Tumor
Normal
Tumor
Normal
Tumor
Sex
Male103 (49.5)20 (60.6)27 (55.1)28 (60.9)44 (77.2)35 (76.1)44 (77.2)
Female105 (50.5)17 (45.9)25 (45.5)38 (64.4)49 (73.1)41 (69.5)53 (79.1)
χ2 (P value)0.97 (0.324)0.62 (0.432)0.03 (0.866)0.1 (0.755)0.28 (0.596)< 0.01 (0.969)
Age at surgery
mean ± SD64.3 ± 14.664.9 ± 14.266.9 ± 15.866.4 ± 14.867.7 ± 15.565.0 ± 14.466.2 ± 15.0
< 65103 (49.5)17 (51.5)26 (53.1)28 (58.3)43 (72.9)34 (70.8)46 (78.0)
≥ 65105 (50.5)20 (54.1)26 (47.3)38 (66.7)50 (76.9)42 (73.7)51 (78.5)
χ2 (P value)< 0.01 (1.00)0.15 (0.694)0.46 (0.498)0.1 (0.755)0.01 (0.915)< 0.01(1.00)
Stage
I29 (13.9)7 (58.3)7 (50.0)9 (50.0)12 (63.2)12 (66.7)17 (89.5)
II77 (37.0)13 (48.1)17 (45.9)21 (56.8)33 (75.0)29 (78.4)39 (88.6)
III68 (32.7)13 (65.0)21 (63.6)22 (68.8)31 (75.6)22 (68.8)27 (65.9)
IV34 (16.3)4 (36.4)7 (35.0)14 (77.8)17 (85.0)13 (72.2)14 (70.0)
χ2 (P value)2.77 (0.429)4.5 (0.212)4.06 (0.255)2.5 (0.476)1.17 (0.760)8.69a (0.034)
5-yr recurrence1
No141 (82.0)28 (51.9)35 (49.3)43 (56.6)61 (70.9)54 (71.1)71 (82.6)
Yes31 (18.0)4 (40.0)9 (60.0)12 (80.0)14 (82.4)11 (73.3)12 (70.6)
χ2 (P value)0.12 (0.731)0.22 (0.639)1.98 (0.160)0.45 (0.504)< 0.01 (1.00)0.65 (0.421)
5-yr all-cause death
No168 (80.8)29 (54.7)43 (51.8)50 (61.0)79 (78.2)59 (72.0)77 (76.2)
Yes40 (19.2)8 (47.1)9 (42.9)16 (69.6)14 (60.9)17 (73.9)20 (87.0)
χ2 (P value)0.07 (0.786)0.24 (0.625)0.26 (0.611)2.15 (0.142)< 0.01 (1.00)0.71 (0.399)
5-yr progression
No155 (74.5)28 (56.0)39 (50.0)45 (58.4)73 (76.8)56 (72.7)74 (77.9)
Yes53 (25.5)9 (45.0)13 (50.0)21 (75.0)20 (69.0)20 (71.4)23 (79.3)
χ2 (P value)0.32 (0.570)< 0.01(1.00)1.75 (0.185)0.38 (0.540)< 0.01 (1.00)< 0.01 (1.00)
Lymphovascular invasion1
No106 (52.5)20 (48.8)25 (48.1)32 (56.1)46 (73.0)41 (71.9)55 (87.3)
Yes96 (47.5)16 (57.1)27 (51.9)34 (72.3)47 (78.3)34 (72.3)41 (68.3)
χ2 (P value)0.19 (0.662)0.04 (0.845)2.26 (0.133)0.23 (0.634)< 0.01 (1.00)5.44a (0.02)
Histological grade1
Well or moderately156 (89.7)27 (48.2)35 (47.3)52 (64.2)67 (74.4)58 (71.6)67 (74.4)
Poor or undifferentiated18 (10.3)6 (100.0)9 (64.3)7 (70.0)14 (82.4)9 (90.0)13 (76.5)
χ2 (P value)3.94a (0.047)0.76 (0.382)< 0.01 (0.99)0.15 (0.697)0.75 (0.387)< 0.01 (1.00)
Lymph node counts1
0-1134 (18.4)7 (63.6)7 (50.0)12 (80.0)15 (83.3)13 (86.7)16 (88.9)
≥ 12151 (81.6)29 (52.7)40 (50.0)50 (61.7)70 (73.7)58 (71.6)70 (73.7)
χ2 (P value)0.07 (0.786)< 0.01 (1.00)1.14 (0.287)0.33 (0.568)0.81 (0.368)1.18 (0.278)
Tumor location1
Colon147 (79.9)28 (50.0)38 (50.7)53 (67.9)62 (70.5)60 (76.9)68 (77.3)
Rectum37 (20.1)8 (80.0)9 (47.4)9 (50.0)23 (92.0)11 (61.1)18 (72.0)
χ2 (P value)1.99 (0.158)< 0.01(1.00)1.35 (0.245)3.76 (0.052)1.17 (0.280)0.08 (0.780)
Adjuvant chemotherapy1
No54 (29.3)10 (58.8)12 (42.9)15 (55.6)25 (73.5)20 (74.1)29 (85.3)
Yes130 (70.7)26 (53.1)35 (53.0)47 (68.1)60 (75.9)51 (73.9)57 (72.2)
χ2 (P value)0.02 (0.898)0.46 (0.499)0.85 (0.358)0.01 (0.971)< 0.01(1.00)1.59 (0.207)
Table 3 Methylation level of sulfatase modifying factor 2 and ADAM metallopeptidase with thrombospondin type 1 motif 5 in normal tissue and tumor tissue (n= 208)

Normal
Tumor
P value
n1
Median
mean ± SD2
n1
Median
mean ± SD2
SUMF2
CpG_1690.40 0.43 ± 0.151040.530.55 ± 0.17< 0.001
CpG_2700.56 0.56 ± 0.111040.760.73 ± 0.13< 0.001
CpG_3700.38 0.39 ± 0.111040.540.54 ± 0.17< 0.001
CpG_7480.64 0.64 ± 0.15800.870.81 ± 0.200.001
ADAMTS5
CpG_1660.06 0.08 ± 0.07950.190.25 ± 0.20< 0.001
CpG_2700.06 0.08 ± 0.061050.200.24 ± 0.18< 0.001
CpG_9690.06 0.07 ± 0.06910.210.25 ± 0.18< 0.001
CpG_10.11690.08 0.10 ± 0.091030.300.34 ± 0.22< 0.001
CpG_12650.09 0.10 ± 0.08980.190.24 ± 0.210.001
CpG_13630.07 0.12 ± 0.14940.150.22 ± 0.220.009
CpG_14.15710.32 0.33 ± 0.051050.430.44 ± 0.11< 0.001
CpG_16710.10 0.11 ± 0.041050.190.22 ± 0.12< 0.001
Table 4 Multivariate 5-year progression and survival analysis of SUMF2 and ADAMTS5 gene
RFS
PFS
OS
cHR (95%CI)aHR (95%CI)1cHR (95%CI)aHR (95%CI)1cHR (95%CI)aHR (95%CI)2
SUMF2 in tumor tissue
CpG_3+CpG_7
Hypomethylation1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference)
Hypermethylation2.37 (0.86-6.55)1.64 (0.55-4.89)2.24 (1.03-4.85)a2.05 (0.91-4.62)2.56 (1.08-6.04)a3.53 (1.35-9.26)a
ADAMTS5 in normal tissue
CpG_2
Hypomethylation1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference)
Hypermethylation0.15 (0.03-0.71)a0.17 (0.03-0.95)a0.57 (0.24-1.37)0.54 (0.21-1.41)0.82 (0.31-2.16)0.94 (0.31-2.85)
CpG_13
Hypomethylation1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference)
Hypermethylation0.20 (0.04-0.97)a0.16 (0.03-0.85)a0.48 (0.19-1.19)0.45 (0.17-1.18)0.50 (0.19-1.30)0.72 (0.24-2.15)